Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2)

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Madsen, Andre ^a,b   Bozickovic, Olivera ^a,b   Bjune, Jan Inge ^a,b   Mellgren, Gunnar ^a,b   Sagen, Jørn V ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE; GLUCOSE; METFORMIN; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN BINDING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTOME;

BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; GLUCONEOGENESIS; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; METABOLISM; PROMOTER REGION;

BIOSYNTHETIC PATHWAYS; CHOLESTEROL; FATTY ACID SYNTHASE, TYPE I; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCONEOGENESIS; GLUCOSE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPOGENESIS; METFORMIN; NUCLEAR RECEPTOR COACTIVATOR 2; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84946887754     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16430     Document Type: Article

References (42)

1. Stashi, E., York, B. & O'Malley, B. W. Steroid receptor coactivators: servants and masters for control of systems metabolism. Trends Endocrinol Metab 25, 337-347, doi: 10.1016/j.tem.2014.05.004 (2014).
2. Johnson, A. B. & O'Malley, B. W. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol 348, 430-439, doi: 10.1016/j.mce.2011.04.021 (2012).
3. York, B. & O'Malley, B. W. Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem 285, 38743-38750, doi: 10.1074/jbc.R110.193367 (2010).
4. Dasgupta, S. et al. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest 125, 1174-1188, doi: 10.1172/JCI76029 (2015).
5. Fenne, I. S. et al. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3′, 5′ -cyclic adenosine 5′ -monophosphate-dependent protein kinase. Endocrinology 149, 4336-4345, doi: 10.1210/en.2008-0037 (2008).
6. Stashi, E. et al. SRC-2 is an essential coactivator for orchestrating metabolism and circadian rhythm. Cell Rep 6, 633-645, doi: 10.1016/j.celrep.2014.01.027 (2014).
7. Chopra, A. R. et al. Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab 13, 35-43, doi: 10.1016/j.cmet.2010.12.001 (2011).
8. Picard, F. et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111, 931-941 (2002).
9. Jeong, J. W. et al. The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. Mol Endocrinol 20, 1138-1152, doi: 10.1210/me.2005-0407 (2006).
10. Chopra, A. R. et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 322, 1395-1399, doi: 10.1126/science.1164847 (2008).
11. Jeong, J. W. et al. The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. Molecular endocrinology 20, 1138-1152, doi: 10.1210/me.2005-0407 (2006).
12. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 1125-1131, doi: 10.1172/JCI15593 (2002).
13. Consoli, A. et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 30, 509-516 (2004).
14. Tran, L. et al. Pharmacologic Treatment of Type 2 Diabetes: Oral Medications. Ann Pharmacother 49, 540-556, doi: 10.1177/1060028014558289 (2015).
15. Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646, doi: 10.1126/science.1120781 (2005).
16. Viollet, B. et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122, 253-270, doi: 10.1042/CS20110386 (2012).
17. Maziere, J. C. et al. The antidiabetic drug metformin decreases cholesterol metabolism in cultured human fibroblasts. Atherosclerosis 71, 27-33 (1988).
18. Carroll, J. S. et al. Genome-wide analysis of estrogen receptor binding sites. Nature genetics 38, 1289-1297, doi: 10.1038/ng1901 (2006).
19. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 108, 1167-1174, doi: 10.1172/JCI13505 (2001).
20. Lin, H. Z. et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6, 998-1003, doi: 10.1038/79697 (2000).
21. Ford, R. J. et al. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J 468, 125-132, doi: 10.1042/BJ20150125 (2015).
22. Matafome, P. et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 27, 54-62, doi: 10.1002/dmrr.1157 (2011).
23. Nar, A. & Gedik, O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46, 113-118, doi: 10.1007/s00592-008-0067-2 (2009).
24. Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proceedings of the National Academy of Sciences of the United States of America 109, 8977-8982, doi: 10.1073/pnas.1201689109 (2012).
25. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11, 390-401, doi: 10.1016/j.cmet.2010.03.014 (2010).
26. Berrabah, W., Aumercier, P., Lefebvre, P. & Staels, B. Control of nuclear receptor activities in metabolism by post-translational modifications. FEBS letters 585, 1640-1650, doi: 10.1016/j.febslet.2011.03.066 (2011).
27. Foretz, M. et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120, 2355-2369, doi: 10.1172/JCI40671 (2010).
28. Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546, doi: 10.1038/nature13270 (2014).
29. Hawley, S. A., Gadalla, A. E., Olsen, G. S. & Hardie, D. G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420-2425 (2002).
30. Pawelczyk, L., Spaczynski, R. Z., Banaszewska, B. & Duleba, A. J. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. European journal of obstetrics, gynecology, and reproductive biology 113, 209-213, doi: 10.1016/j.ejogrb.2003.09.031 (2004).
31. De Leo, V., La Marca, A., Orvieto, R. & Morgante, G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism 85, 1598-1600, doi: 10.1210/jcem.85.4.6560 (2000).
32. Dasgupta, S. et al. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. The Journal of clinical investigation 125, 1174-1188, doi: 10.1172/JCI76029 (2015).
33. Fenne, I. S. et al. Downregulation of steroid receptor coactivator-2 modulates estrogen-responsive genes and stimulates proliferation of mcf-7 breast cancer cells. PloS one 8, e70096, doi: 10.1371/journal.pone.0070096 (2013).
34. Zhang, J. et al. Dietary obesity-induced Egr-1 in adipocytes facilitates energy storage via suppression of FOXC2. Scientific reports 3, 1476, doi: 10.1038/srep01476 (2013).
35. Xu, B. et al. Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers. International journal of clinical and experimental pathology 7, 2883-2893 (2014).
36. Gokey, N. G., Lopez-Anido, C., Gillian-Daniel, A. L. & Svaren, J. Early growth response 1 (Egr1) regulates cholesterol biosynthetic gene expression. The Journal of biological chemistry 286, 29501-29510, doi: 10.1074/jbc.M111.263509 (2011).
37. Margel, D. et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31, 3069-3075, doi: 10.1200/JCO.2012.46.7043 (2013).
38. Altarejos, J. Y. & Montminy, M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12, 141-151, doi: 10.1038/nrm3072 (2011).
39. Koo, S. H. et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111, doi: 10.1038/nature03967 (2005).
40. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174, doi: 10.1172/JCI13505 (2001).
41. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 67, 491-498 (2002).
42. Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8, 1551-1566, doi: 10.1038/nprot.2013.092 (2013).